Press releases
- Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutical Group for its mRNA Vaccine Business
- Everest Medicines Announces that Topline Results from Chinese Subpopulation Consistent With Global Phase 3 NefIgArd Study Part A Analysis
- Everest Medicines Submits New Drug Application in Hong Kong for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
- Everest Medicines Announces that Licensing Partner Pfizer Reports Positive Topline Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients, Underscoring Best-in-Class Potential
- Everest Medicines Announces Financial Results for Full Year Ended December 31, 2021
- Everest Medicines to Announce Full-Year 2021 Financial Results on March 29, 2022
- Everest Medicines Enters into Agreement with Calliditas Therapeutics, Expanding Territory License to Develop and Commercialize NEFECON in South Korea
- Everest Medicines Announces that Licensing Partner Venatorx Pharmaceuticals Reports Positive Results from Pivotal Phase 3 Cefepime-Taniborbactam Trial
More ▼
Key statistics
As of last trade, Everest Medicines Ltd (6HN:DEU) traded at 2.60, 63.21% above the 52 week low of 1.59 set on Mar 15, 2022.
52-week range
Markit short selling activity
Open | 2.63 |
---|---|
High | 2.68 |
Low | 2.36 |
Bid | 2.60 |
Offer | 2.68 |
Previous close | 2.73 |
Average volume | 290.00 |
---|---|
Shares outstanding | 301.22m |
Free float | 301.22m |
P/E (TTM) | -- |
Market cap | 5.33bn HKD |
EPS (TTM) | -3.98 HKD |
Data delayed at least 15 minutes, as of May 19 2022 10:09 BST.
More ▼